KD Logo

Taking a look at what insiders are doing to gauge the Nurix Therapeutics Inc (NRIX)’s direction

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Nurix Therapeutics Inc shares valued at $400,216 were sold by van Houte Hans on Jun 20 ’24. At $20.01 per share, van Houte Hans sold 20,000 shares. The insider’s holdings dropped to 48,333 shares worth approximately $1.01 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Also, Ring Christine sold 1,864 shares, netting a total of over 31,721 in proceeds. Following the sale of shares at $17.02 each, the insider now holds 19,838 shares.

Before that, Ring Christine had sold 1,900 shares from its account. In a trade valued at $32,319, the Chief Legal Officer traded Nurix Therapeutics Inc shares for $17.01 each. Upon closing the transaction, the insider’s holdings decreased to 1,900 shares, worth approximately $0.42 million.

Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in early March. As of February 28, 2023, Oppenheimer has initiated its “an Outperform” rating for NRIX. Earlier on October 11, 2022, Morgan Stanley initiated its rating. Their recommendation was “an Equal-weight” for NRIX stock.

Analyzing NRIX Stock Performance

During the last five days, there has been a surge of approximately 27.09%. Over the course of the year, Nurix Therapeutics Inc shares have jumped approximately 103.20%. Shares of the company reached a 52-week high of $21.16 on 06/20/24 and a 52-week low of $7.65 on 01/29/24. A 50-day SMA is recorded $15.05, while a 200-day SMA reached $10.55. Nevertheless, trading volume fell to 2.74 million shares from 2.84 million shares the previous day.

Support And Resistance Levels for Nurix Therapeutics Inc (NRIX)

According to the 24-hour chart, there is a support level at 19.04, which, if violated, would cause prices to drop to 17.12. In the upper region, resistance lies at 22.03. The next price resistance is at 23.09. RSI (Relative Strength Index) is 72.40 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.72, which suggests the price will increase in the coming days. Percent R is at 2.83%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Most Popular